Adocia
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Adocia - overview
Established
2005
Location
Lyon, -, France
Primary Industry
Biotechnology
About
Adocia is a biotechnology company dedicated to developing innovative treatments for diabetes and obesity, focusing on advanced insulin formulations and metabolic hormones to enhance patient care. Founded in 2005 and headquartered in Lyon, France, Adocia specializes in biopharmaceutical innovations for diabetes management and obesity. The company, founded by Olivier Soula, has undergone significant developments, including its IPO in March 2012, to expand its research and commercialization efforts. Olivier Soula leads the company as CEO, building upon his extensive experience in biotechnology.
Adocia specializes in the development of innovative treatments primarily for diabetes and obesity, focusing on the formulation of advanced insulins and metabolic hormones. Their core product offerings include proprietary formulations that enhance the efficacy and usability of already-approved peptides and proteins, as well as immunoprotective scaffolds designed for cell therapies. These products are intended to improve glycemic control and weight management for patients suffering from type 1 and type 2 diabetes, alongside obesity-related metabolic issues. Adocia's products target pharmaceutical companies and healthcare providers in various global markets, including Europe and North America, who seek to license these innovative solutions for manufacturing and distribution.
In the most recent year of 2022, Adocia reported a revenue of EUR 12,062,836, along with an EBITDA of EUR -1,266,666. 3. The company's revenue generation is primarily through strategic partnerships and licensing agreements following successful human trial validations of their products, allowing pharmaceutical firms to commercialize their proprietary formulations. Adocia's strategy for future growth includes the development and launch of new products aimed at enhancing treatment options for diabetes and obesity.
The company plans to further expand its market reach in Europe and North America within the next few years. The recent funding of EUR 14. 000 mn raised during the Series B round will support these initiatives, focusing on product development and scaling operations.
Current Investors
Idinvest Partners, Eiffel Investment Group, Eurazeo
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Website
www.adocia.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Adocia - timeline of key events
Adocia - financials
| Fiscal Year Ended | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 3,995,000 | 5,588,000 | 704,000 | 36,936,000 | 22,488,000 | 19,469,000 | 47,389,000 | 2,143,000 | 841,000 | 1,444,000 | - | - | - |
| % Revenue Growth (YoY) | - | 39.9% | (87.4%) | 5146.6% | (39.1%) | (13.4%) | 143.4% | (95.5%) | (60.8%) | 71.7% | - | - | - |
| EBITDA (USD) | (5,677,000) | (3,915,000) | (16,814,000) | 10,610,000 | (7,261,000) | (7,167,000) | 10,751,000 | (20,864,000) | (19,950,000) | (18,208,000) | - | - | - |
| Operating Income (USD) | (6,070,000) | (4,302,000) | (17,161,000) | 10,103,000 | (8,001,000) | (8,180,000) | 9,707,000 | (22,021,000) | (21,148,000) | (19,366,000) | - | - | - |
| Operating Margin | (151.9%) | (77.0%) | (2437.6%) | 27.4% | (35.6%) | (42.0%) | 20.5% | (1027.6%) | (2514.6%) | (1341.1%) | - | - | - |
| % EBITDA Margin | (142.1%) | (70.1%) | (2388.4%) | 28.7% | (32.3%) | (36.8%) | 22.7% | (973.6%) | (2372.2%) | (1260.9%) | - | - | - |
| NET Income (USD) | (5,995,000) | (4,293,000) | (20,715,000) | 12,553,000 | (7,892,000) | (8,550,000) | 7,615,000 | (18,603,000) | (23,324,000) | (22,754,000) | - | - | - |
| % Net Margin | (150.1%) | (76.8%) | (2942.5%) | 34.0% | (35.1%) | (43.9%) | 16.1% | (868.1%) | (2773.4%) | (1575.8%) | - | - | - |
Adocia - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Debt | Completed | Adocia | - |
Displaying 1 - 1 of 1
Adocia - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.